Evidence map›Paper›PMID 33145068›Full record

ArticleJournal of thoracic disease2020

Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples.

Zhengwei Dong, Ziyang Cao, Wei Wu, Liping Zhang, Likun Hou, Wei Zhang, Chunyan Wu

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Zhengwei DongDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Ziyang CaoDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Wei WuDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Liping ZhangDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Likun HouDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Wei ZhangDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Chunyan WuDepartment of Pathology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Shanghai Pulmonary Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytology samples are the main resources to detect driver oncogene alterations for advanced lung cancer patients. To explore the value of liquid-based cytology in the detection of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC), we analyzed data from a large cohort of EGFR mutation-positive patients.

methodsWe analyzed the clinicopathological characteristics of 8,029 NSCLC cases tested for EGFR mutation by liquid-based cytology specimens and 1,934 NSCLC cases tested by formalin-fixed and paraffine-embedded (FFPE) samples in the Shanghai Pulmonary Hospital from September 2015 to December 2019. Before detection, we evaluated the number of tumor cells in the liquid-based cytology slide, and samples with more than 50 tumor cells and visible sediment were selected for DNA extraction after centrifugation.

resultsThe positive rate of EGFR mutation in liquid-based cytology-tested cases was 47.18%, higher than the 41.37% tested through FFPE sample (P<0.01). Accordingly, the mutation rate of EGFR in adenocarcinoma (AC) and NSCLC was higher than that of the FFPE sample (60.01%

conclusionsUsing quality control and standard procedure, it was found that liquid-based cytology specimen testing is a convenient and reliable method of EGFR detection, as validated by analysis of a large cohort. EGFR mutation detection should also be carried out in NSCLC patients diagnosed by cytology more than in AC patients.

Indexed as

cytology specimensdrive mutationepidermal growth factor receptor (EGFR)liquid-based cytologyNon-small cell lung cancer (NSCLC)

Identifiers

PMID33145068
PMCPMC7578468
OpenAlexW3085126999

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.